Signaling Pathway
Enuzovimab (HFB-30132A) is a monoclonal antibody specifically developed to target the SARS-CoV-2 Omicron variant. It exhibits high-affinity binding to the spike (S) protein of the virus, offering potential utility in therapeutic interventions against this strain.
重要通知：仅供研究使用。我们不向患者销售。
| Discription | Enuzovimab (HFB-30132A) is a monoclonal antibody specifically developed to target the SARS-CoV-2 Omicron variant. It exhibits high-affinity binding to the spike (S) protein of the virus, offering potential utility in therapeutic interventions against this strain. |
||
|---|---|---|---|
| Targets |
|
Calculate the dilution required to prepare a stock solution. This equation is commonly abbreviated as: C1V1 = C2V2
